Jump to content

Search the Community

Showing results for tags 'metastasis'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 4 results

  1. Jim Marshall (not a doctor) said ... Metastases (mets) are cancers growing away from the original cancer. In prostate cancer, metastases are often found growing in bone. This can become very painful. A common treatment for a painful met is a strong dose of radiation (X-rays) focussed on the met. A special problem arises at the end of life. No one wants to give a treatment that won't work in time. So Rachel McDonald and her colleagues looked at how quickly radiation to one or two mets gave pain relief and a better quality of life. The
  2. Click on this link to read the article in Scientific American.
  3. Research performed at the University of Queensland has shown that a diet, which is high in cholesterol, might increase the spread of prostate cancer tumours to lymph nodes, lungs and bones. Click here to read news article.
  4. Paul Edwards

    Cabozantinib - COMET-2 Clinical Trial

    Thanks to Russ Wilson for pointing out that a clinical trial of Cabozantinib is currently recruiting in Queensland, New South Wales, Victoria and Western Australia for men with metastatic hormone-refractory prostate cancer who have had chemotherapy. Cabozantinib (marketed under the tradename Cometriq, formerly known as XL184) has been shown to reduce tumor growth, metastasis and angiogenesis. It was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer. It is currently undergoing clinical trials for the treatment of prostate, ovarian, brain, melanom
×
×
  • Create New...